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Introduction {#sec001}
============

*Escherichia coli* is one of the most common pathogens in nosocomial and community-acquired infections in humans. Fosfomycin is a broad-spectrum antibacterial agent against Gram-positive and Gram-negative bacteria; it inhibits the UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), responsible for the formation of UDP-GlcNAc-enolpyruvate in the biosynthesis of cell-wall peptidoglycans \[[@pone.0135269.ref001],[@pone.0135269.ref002]\]. Fosfomycin enters the *E*. *coli* cell by using one of two transport systems: the glycerol-3-phosphate transport system (GlpT) or the hexose phosphate transport system (UlpT) \[[@pone.0135269.ref003],[@pone.0135269.ref004]\]. The prevalence of fosfomycin resistance in *E*. *coli* remains low \[[@pone.0135269.ref005]--[@pone.0135269.ref008]\], but several resistance mechanisms to fosfomycin have been reported. Mutations in the *glpT* or *uhpT* genes can decrease the uptake of fosfomycin via the transport systems and give rise to fosfomycin resistance \[[@pone.0135269.ref004],[@pone.0135269.ref009],[@pone.0135269.ref010]\]. Resistance against fosfomycin can also be conferred by mutations in the *murA* gene, resulting in either reduced affinity between MurA and fosfomycin or through the over-expression of MurA \[[@pone.0135269.ref011],[@pone.0135269.ref012]\]. In addition, the presence of the plasmid-borne *fosA*, *fosA* ~*3*~ and *fosC* ~*2*~ genes, which encode fosfomycin-modifying enzymes, can inactivate the drug by catalyzing the covalent addition of glutathione to fosfomycin \[[@pone.0135269.ref013]\].

However, little is known about the rate of resistance or *E*. *coli* mechanisms of resistance to fosfomycin in Mainland China. Thus, here we investigated several fosfomycin resistance mutations and the mobility of the *fosA3* gene.

Material and Methods {#sec002}
====================

Bacterial strains {#sec003}
-----------------

A total of 1109 non-duplicate *E*. *coli* strains isolated from urine, sputum, blood and pus samples were collected as part of standard patient care from July 2009 to June 2010 in 20 widely dispersed tertiary hospitals. *E*. *coli* ATCC 25922 \[[@pone.0135269.ref014]\] was used for quality control for susceptibility testing and the sodium azide-resistant *E*. *coli* J53 \[[@pone.0135269.ref015]\] strain was used as a recipient in the mating experiment.

Ethics {#sec004}
------

The samples were collected from hospitals participating in the Ministry of Health National Antimicrobial Resistance Surveillance Net (Mohnarin) study. No ethical approval or informed consent was required due to the retrospective nature of the study. All patient identifiable information was removed from the samples before the authors received them for analysis. The authors were not involved in the treatment and had no direct contact with the patients.

Susceptibility testing {#sec005}
----------------------

Susceptibility to antimicrobial agents was determined using the agar dilution method according to the Clinical and Laboratory Standards Institute \[[@pone.0135269.ref014]\]. The following antimicrobial agents were tested: fosfomycin trometamol, piperacillin-tazobactam, cefuroxime, cefotaxime, cefepime, imipenem, amikacin, levofloxacin, and nitrofurantoin. Based on minimum inhibitory concentrations (MIC), *E*. *coli* were classified as fosfomycin-susceptible (MIC ≤64mg/L), fosfomycin-intermediate (MIC = 128mg/L) and fosfomycin-resistant (MIC ≥256 mg/L). Extended-spectrum beta-lactamase (ESBL) producing isolates were detected according to previously described methods \[[@pone.0135269.ref014]\]. The reference strain *E*. *coli* ATCC 25922 was used as the positive control. The spontaneous fosfomycin resistance rate for *E*. *coli* J53 strain determined in our research was \<10^−8^.

PCR amplification of genes and sequence analysis {#sec006}
------------------------------------------------

Detection of the *murA*, *glpT*, *uhpT*, *fosA*, *fosA* ~*3*~ and *fosC* genes was performed in fosfomycin non-susceptible *E*. *coli* strains (intermediate and resistant *E*. *coli* strains; MIC ≥128 mg/L), and the primers used are listed in [Table 1](#pone.0135269.t001){ref-type="table"} \[[@pone.0135269.ref016]--[@pone.0135269.ref018]\]. Sequence analysis was performed with a Dye primer and a Dye Terminator cycle sequencing kit (Applied Biosystems) and with a 310 gene analyzer (ABI Prism).

10.1371/journal.pone.0135269.t001

###### Oligonucleotide primers employed.

![](pone.0135269.t001){#pone.0135269.t001g}

  Amplified gene   Primer   Sequence                          Amplicon size (bp)   Ref
  ---------------- -------- --------------------------------- -------------------- -----
  *MurA*           MF       `5'-AAACAGCAGACGGTCTATGG-3'`      1260                 19
                   MR       `5''-CCATGAGTTTATCGACAGAACG-3'`                        
  *uhpT*           UF       `5'-TTTTTGAACGCCCAGACACC-3'`      1392                 19
                   UR       `5'-AGTCAGGGGCTATTTGATGG-3'`                           
  *glpT*           GF       `5'-GCGAGTCGCGAGTTTTCATTG-3'`     1359                 19
                   GR       `5'-GGCAAATATCCACTGGCACC-3'`                           
  *fosA*           FAF      `5'-ATCTGTGGGTCTGCCTGTCGT-3'`     271                  16
                   FAR      `5'-ATGCCCGCATAGGGCTTCT-3'`                            
  *fosC* ~*2*~     FCF      `5'-TGGAGGCTACTTGGATTTG-3'`       217                  16
                   FCR      `5'-AGGCTACCGCTATGGATTT-3'`                            
  *fosA* ~*3*~     FA3F     `5'-GCGTCAAGCCTGGCATTT-3'`        282                  16
                   FA3R     `5'-GCCGTCAGGGTCGAGAAA-3'`                             

Conjugation experiments {#sec007}
-----------------------

The conjugation experiments were carried out to determine the mobility of *fosA* ~*3*~ gene from azide-sensitive isolates as donors to azide-resistant *E*. *coli* J53 as the recipient. Overnight cultures of 0.05 ml of the donor and 0.45 mL of the recipient strains were added to 3 mL of fresh Mueller Hinton (MH) broth (Oxoid Ltd., Basingstoke, Hampshire, United Kingdom), then incubated and gently stirred at 37°C for 12 hours. 0.1 mL of the mixtures were plated on MH agar (Oxoid Ltd., Basingstoke, Hampshire, United Kingdom) containing glucose-6-phosphate (25 mg/L), sodium azide (100 mg/L) and fosfomycin (Zambon Group, Milan, Italy) (32 mg/L) and incubated for 48 hours for selection. The conjugative transfer frequency was calculated as the ratio of the number of conjugants to the number of donors.

Statistical analyses {#sec008}
--------------------

Statistical tests were performed using Social Sciences software for Windows Version 14.0 (SPSS, Inc., Chicago, IL, USA). Enumeration data were expressed as percentage values. The differences in susceptibility between the groups were compared using the Chi-square test or Fisher's exact test. The differences between the groups were considered significant if the p-values were smaller than 0.05 (two-sided test). The Bonferroni method was used to adjust the significant levels (0.05/3 = 0.0167) in multiple comparisons between any two levels of the susceptibility outcome.

Results {#sec009}
=======

1023/1109 (92.2%) of the *E*. *coli* isolates were susceptible to fosfomycin. The susceptibility rates of the isolates from urine, sputum, blood and pus samples were 95.0%, 87.1%, 93.3% and 93.3%, respectively. MIC~50~ of the strains from different specimen types were all 0.25 mg/L, whilst the MIC~90~ of the strains from urine, sputum, blood and pus samples were 4, 128, 16 and 32 mg/L, respectively ([Table 2](#pone.0135269.t002){ref-type="table"}). The ESBL-positive rates were 67.2% (687/1023), 85.7% (30/35) and 90.2% (46/51) among fosfomycin-susceptible, intermediate and resistant isolates, respectively.

10.1371/journal.pone.0135269.t002

###### Fosfomycin susceptibility of *E*. *coli* strains from different samples by source.

![](pone.0135269.t002){#pone.0135269.t002g}

  Sample source   No. of isolates   ESBL(%)   No. of isolates inhibited at fosfomycin MIC (mg/L) of   MIC~50~(mg/L)   MIC~90~(mg/L)   S (%)   I (%)   R (%)                                                                     
  --------------- ----------------- --------- ------------------------------------------------------- --------------- --------------- ------- ------- ------- ---- ---- ---- ---- ---- ---- ---- ---- ------ ----- ------ ----- -----
  urine           262               65.9      7                                                       59              116             34      15      4       4    1    4    4    1    3    8    2    0.25   4     95.0   1.2   3.8
  sputum          264               77.9      7                                                       47              94              27      23      9       10   5    2    2    4    15   12   7    0.25   128   87.1   5.7   7.2
  blood           343               67.9      6                                                       72              135             59      14      9       9    5    6    2    3    7    9    7    0.25   16    93.3   2.0   4.7
  pus             240               63.3      5                                                       46              90              38      19      5       4    3    3    6    5    10   3    3    0.25   32    93.3   4.2   2.5
  Total           1109              68.8      25                                                      224             435             158     71      27      27   14   15   14   13   35   32   19   0.25   32    92.2   3.2   4.6

ESBL---extended spectrum β-lactamases; MIC---minimum inhibitory concentration; MIC~50~ --minimum concentration that inhibits 50% of the growth; MIC~90~ --minimum concentration that inhibits 90% of the growth; S---susceptibility; I---intermediate; R---resistance

The antimicrobial resistance rates stratified by fosfomycin susceptibility categories are summarized in [Table 3](#pone.0135269.t003){ref-type="table"}. Fosfomycin-resistant isolates were significantly more likely to be ESBL positive than were fosfomycin-susceptible isolates (P \<0.001). In addition, the resistance rates for piperacillin-tazobactam, cefuroxime, cefotaxime, amikacin and nitrofurantoin were significantly higher in fosfomycin-resistant isolates than fosfomycin-susceptible isolates (P \< 0.0167 for all comparisons).

10.1371/journal.pone.0135269.t003

###### Antimicrobial resistance of *Escherichia coli* stratified by fosfomycin susceptibility.

![](pone.0135269.t003){#pone.0135269.t003g}

                                                      \% resistant   *P* [^b^](#t003fn004){ref-type="table-fn"}                                                 
  --------------------------------------------- ----- -------------- -------------------------------------------- --------------------------------------------- ----------
  Agent[^a^](#t003fn002){ref-type="table-fn"}                                                                                                                   
                                                TZP   3.8            11.4                                         13.7[\*\*](#t003fn006){ref-type="table-fn"}   0.002
                                                CXM   71.1           94.3[\*](#t003fn005){ref-type="table-fn"}    98.0[\*\*](#t003fn006){ref-type="table-fn"}   \< 0.001
                                                CTX   70.0           94.3[\*](#t003fn005){ref-type="table-fn"}    98.0[\*\*](#t003fn006){ref-type="table-fn"}   \< 0.001
                                                FEP   34.1           48.6                                         49.0                                          0.023
                                                IMP   0.2            0                                            2.0                                           0.215
                                                AMK   4.2            37.1[\*](#t003fn005){ref-type="table-fn"}    35.3[\*\*](#t003fn006){ref-type="table-fn"}   \< 0.001
                                                LVX   58.7           68.6                                         60.8                                          0.494
                                                TET   77.4           77.1                                         90.2                                          0.098
                                                NIT   1.4            14.3[\*](#t003fn005){ref-type="table-fn"}    11.8[\*\*](#t003fn006){ref-type="table-fn"}   \< 0.001
  ESBL positive                                       67.2           85.7                                         90.2[\*\*](#t003fn006){ref-type="table-fn"}   \< 0.001

Fos-S, fosfomycin---susceptible (MIC ≤64 mg/L); Fos-I, fosfomycin---intermediate (MIC = 128 mg/L); Fos-R, fosfomycin-resistant (MIC ≥256 mg/L); ESBL---extended spectrum β-lactamases.

^a^Drug abbreviations: FOS, fosfomycin trometamol; TZP, piperacillin-tazobactam;

CXM, cefuroxime; CTX, cefotaxime; FEP, cefepime; IMP, imipenem; AMK, amikacin; LVX, levofloxacin; TET, tetracycline; NIT, nitrofurantoin.

^b^ *P* value for comparison of resistance rates between fosfomycin-susceptible and fosfomycin-resistant isolates.

\*compared to FOS-S, *P* \< 0.0167

\*\*compared to FOS-R, *P* \< 0.0167

In 86 fosfomycin non-susceptible *E*. *coli* strains, amino-acid substitutions Val389Ile, Asp390Ala, Gln59Lys and Glu139Lys were found in MurA of *E*. *coli* strains J621, E261, E374 and R162, respectively. In addition, amino-acid substitutions Ile4Val and Gly84Asp were found in GlpT of *E*. *coli* strains H039 and R538, respectively. In strain Q446, the GlpT protein was truncated due to deletion of nucleotide 401A. Amino acid substitutions Thr144Pro and Pro173Ser were found in the GlpT of strains R046 and P305. Amino acid substitutions Ala12Val and Gln437Cys were found in GlpT of strains T229 and T297. The *uhpT* gene was absent from 18 of the test strains. 69 *E*. *coli* isolates were positive for *fosA* ~*3*~, yet no *fosC* ~*2*~ or *fosA* genes were detected among these isolates ([Table 4](#pone.0135269.t004){ref-type="table"}). The *fosA* ~*3*~ gene was able to transfer at frequencies varying from 1.1×10^−7^ to 9.9×10^−6^ between the donor and recipient in 29 isolates tested.

10.1371/journal.pone.0135269.t004

###### Characterization of fosfomycin non-susceptible *E*. *coli* isolates.

![](pone.0135269.t004){#pone.0135269.t004g}

  *E*. *coli* strain                                                                                                                                                                                                                               No. of isolates   MIC range (mg/L)   Amino acid substitutions or sequence variations[^a^](#t004fn002){ref-type="table-fn"}   *fosA* ~*3*~                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------- ------------------ --------------------------------------------------------------------------------------- -------------- -------------------------------------------------- ----
  J443,J648,O241,L026,L088,Q097,D353,D503,G001,H256,A083,D360,R214,R494                                                                                                                                                                            14                128-\>256          None[^c^](#t004fn004){ref-type="table-fn"}                                              None           No peptide[^b^](#t004fn003){ref-type="table-fn"}   \+
  H039                                                                                                                                                                                                                                             1                 256                Ile4Val                                                                                 None           No peptide                                         \+
  K077,K105,N182,O013,O065,O250,P273L196,M094,M098,G198,R419,E042,E110,E169,E380,D224,D271,D440,D468,D542,A019,B050,C024,C049,C254,C282,Q079,Q108,R079,R057,Q008,Q056,F040,F070,G160,G383,D014,D265,T335,T436,T038,T108,T211,R259,R421,R143,R145   48                128-\>256          None                                                                                    None           None                                               \+
  E261                                                                                                                                                                                                                                             1                 128                None                                                                                    Asp390Ala      None                                               \+
  E374                                                                                                                                                                                                                                             1                 256                None                                                                                    Gln59Lys       None                                               \+
  T229,T297                                                                                                                                                                                                                                        2                 \>256              Gly437Cys                                                                               None           None                                               \+
  R538                                                                                                                                                                                                                                             1                 \>256              Gly84Asp                                                                                None           None                                               \+
  R046                                                                                                                                                                                                                                             1                 256                Thr144Pro,Pro173Ser                                                                     None           None                                               \+
  J609,L229,Q493,P303,Q091,G199,R120,R144,R206                                                                                                                                                                                                     9                 128--256           None                                                                                    None           None                                               −
  Q446                                                                                                                                                                                                                                             1                 128                Truncated to 206 aa (deletion of 401A)                                                  None           None                                               −
  P305                                                                                                                                                                                                                                             1                 128                Thr144Pro,Pro173Ser 173Ser                                                              None           None                                               −
  R162                                                                                                                                                                                                                                             1                 128                None                                                                                    GlU139Lys      None                                               −
  G182,G316                                                                                                                                                                                                                                        2                 256                None                                                                                    None           No peptide                                         −
  J621                                                                                                                                                                                                                                             1                 128                None                                                                                    Val389Ile      No peptide                                         −

MIC---minimum inhibitory concentration; GlpT---glycerol-3-phosphate transport system; MurA---UDP-N-acetylglucosamine enolpyruvyl transferase; UlpT---hexose phosphate transport system.

^a^Genetic mutations are shown in brackets.

^b^Loss of the entire gene.

^c^No amino acid substitutions were found.

Discussion {#sec010}
==========

Fosfomycin has been introduced in clinical practice for about 30 years. However, this antibacterial agent is still not commonly used in China, and the fosfomycin resistance rate in clinical *E*. *coli* isolates remains very low \[[@pone.0135269.ref018]\]. In this study, only 7.8% (86/1109) of *E*. *coli* isolates were fosfomycin non-susceptible with a high ESBL-positive rate and levofloxacin-resistant rate. Among the fosfomycin-resistant isolates, the ESBL-positive rates were higher than in fosfomycin-susceptible isolates.

Fosfomycin inactivates the MurA enzyme by binding to the active site of its Cys-115 residue \[[@pone.0135269.ref019],[@pone.0135269.ref020]\]. The amino acid Asp369Asn and Leu370Ile substitutions have been reported in fosfomycin- resistant *E*. *coli* isolates MSC17327 and MSC17323. Inspection of the crystal structure of *E*. *coli* MurA complexed with fosfomycin does not suggest an obvious role for Asp-369 and Leu-370 in the protein-inhibitor interaction \[[@pone.0135269.ref016]\]. In our study, the MurA substitutions of Val389Ile, Asp390Ala, Gln59Lys and Glu139Lys were found in four *E*. *coli* strains. However, further investigations are needed to find out whether the substitutions contribute to fosfomycin resistance.

Fosfomycin is transported into cells via two pathways: the glycerol-3-phosphate or the hexose phosphate transport systems. Several studies have reported *E*. *coli* fosfomycin resistance due to the defects in GlpT or UhpT \[[@pone.0135269.ref009],[@pone.0135269.ref013],[@pone.0135269.ref016]\]. In this study, mutations in the *glpT* gene were found in six *E*. *coli* strains, all of which resulted in amino acid substitutions in GlpT. In addition, single nucleotide deletion in the *glpT* gene, which would lead to a truncation of the GlpT sequence, was also detected.

Alteration in the chemical structure of fosfomycin by FosA~3~, a protein encoded by the *fosA* ~*3*~ gene, was previously reported in three *E*. *coli* strains in Japan in 2010 for the first time \[[@pone.0135269.ref013]\]. In our study, over 80% of fosfomycin non-susceptible *E*. *coli* strains (69/86) harbored the *fosA* ~*3*~ gene, which indicated that it is the main mechanism responsible for fosfomycin resistance in Mainland China. The *fosA* ~*3*~ gene identified in 42% isolates (29/69) can transfer between different *E*.*coli* strains. Previous research has suggested that the *fosA* ~*3*~ gene is encoded on a conjugated plasmid \[[@pone.0135269.ref021],[@pone.0135269.ref022]\]. As the mobility of this gene may accelerate the dissemination of fosfomycin resistance around the world, future research is warranted to confirm this for *E*. *coli*.
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